Search

CN-121987783-A - MIL-101 (Fe)/MoS-based2Composite nano material of/Ce 6 and preparation method and application thereof

CN121987783ACN 121987783 ACN121987783 ACN 121987783ACN-121987783-A

Abstract

The invention discloses a MIL-101 (Fe)/MoS 2 /Ce 6-based composite nanomaterial, which comprises MIL-101 (Fe)/MoS 2 and Ce6, wherein the mass ratio of MIL-101 (Fe)/MoS 2 to Ce6 is 50-200:10-80, and in MIL-101 (Fe)/MoS 2 , the mass ratio of MIL-101 (Fe) to MoS 2 is 100-500:10-80. The invention also discloses a preparation method of the MIL-101 (Fe)/MoS 2 /Ce 6-based composite nano material and application of the composite nano material in preparation of antitumor drugs.

Inventors

  • WEN RONG
  • SONG YANNAN

Assignees

  • 广州创赛生物医用材料有限公司

Dates

Publication Date
20260508
Application Date
20260130

Claims (10)

  1. 1. A composite nano material based on MIL-101 (Fe) MoS 2 Ce6 is characterized by comprising MIL-101 (Fe)/MoS 2 and Ce6, wherein the mass ratio of MIL-101 (Fe)/MoS 2 to Ce6 is 50-200:10-80, and in MIL-101 (Fe)/MoS 2 , the mass ratio of MIL-101 (Fe) to MoS 2 is 100-500:10-80.
  2. 2. The composite nanomaterial of claim 1, wherein the mass ratio of MILs-101 (Fe)/MoS 2 to Ce6 is 100:10 and the mass ratio of MILs-101 (Fe) to MoS 2 is 300:40.
  3. 3. A method for preparing the MILs-101 (Fe)/MoS 2 /Ce 6-based composite nanomaterial according to claim 1 or 2, characterized by comprising the steps of: S1, synthesizing MIL-101 (Fe) by taking FeCl 3 ·6H 2 O as an iron source and adopting a hydrothermal method; S2, synthesizing MIL-101 (Fe)/MoS 2 by adopting an in-situ growth method to synthesize MIL-101 (Fe)/MoS 2 ; And step S3, synthesizing MIL-101 (Fe)/MoS 2 /Ce 6, namely loading the photosensitizer Ce6 to MIL-101 (Fe)/MoS 2 by adopting an impregnation method to obtain MIL-101 (Fe)/MoS 2 /Ce 6.
  4. 4. The method according to claim 3, wherein in the step S1, feCl 3 ·6H 2 O and terephthalic acid are dissolved in N, N-dimethylformamide, polyvinylpyrrolidone and acetic acid are added, the solution is sufficiently stirred, then the solution is kept at 110 ℃, after the hydrothermal reaction is finished, the obtained precipitate is centrifuged and washed with N, N-dimethylformamide, and washed with absolute ethyl alcohol, and dried, thereby obtaining MILs-101 (Fe).
  5. 5. The method of claim 4, wherein FeCl 3 ·6H 2 O comprises terephthalic acid, N-dimethylformamide, polyvinylpyrrolidone, acetic acid= (100-800 mg), 100-500 mg, 10-50 mL, 100-300 mg, and 0.5-2 mL.
  6. 6. A method according to claim 3, wherein in step S2, moS 2 is ultrasonically dispersed in N, N-dimethylformamide, followed by adding to a solution of MILs-101 (Fe) -containing N, N-dimethylformamide, stirring thoroughly, then incubating the solution at 150 ℃, ending the reaction, cooling to room temperature, centrifuging the obtained precipitate and washing with N, N-dimethylformamide, washing with absolute ethanol, and drying to obtain MILs-101 (Fe)/MoS 2 .
  7. 7. The method of claim 6, wherein 10-80 mg of MoS 2 is dispersed in 5-15 mL of N, N-dimethylformamide, and 100-500 mg MIL-101 (Fe) is dispersed in 5-15 mL of N, N-dimethylformamide.
  8. 8. A method according to claim 3, wherein in the step S3, MILs-101 (Fe)/MoS 2 is dispersed in N, N-dimethylformamide, ce6 is added to the mixture, stirred overnight in a dark place, and after the reaction, the obtained precipitate is centrifuged and washed, and freeze-dried to obtain a MILs-101 (Fe)/MoS 2 /Ce 6 based composite nanomaterial.
  9. 9. The method according to claim 8, wherein in the step S3, MILs-101/(Fe) MoS 2 :n, N-dimethylformamide:ce6= 50~200 mg:5~25 mL:10~80 mg.
  10. 10. The use of a MILs-101 (Fe)/MoS 2 /Ce 6-based composite nanomaterial according to claim 1 or 2 in the preparation of an antitumor drug.

Description

MIL-101 (Fe)/MoS 2/Ce 6-based composite nanomaterial and preparation method and application thereof Technical Field The invention belongs to the field of biological medicine, and in particular relates to a MIL-101 (Fe)/MoS 2/Ce 6-based composite nano material, and a preparation method and application thereof. Background Gastric cancer is one of the most common malignant tumors worldwide, with very poor prognosis for advanced patients. The current clinical treatment means, including surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy, have limitations on the efficacy of advanced or recurrent gastric cancer. Among these, immune checkpoint inhibitors hold promise for some patients, but have limited overall response rates and face primary or secondary drug resistance problems. Therefore, the development of novel, efficient, low-toxicity therapeutic strategies is an urgent clinical need. In recent years, with the cross-fusion of nanotechnology and biomaterials, nanomedicine has provided a new paradigm for cancer treatment. Wherein, the multifunctional nano platform is utilized to cooperatively integrate a plurality of treatment modes (such as photo-thermal treatment PTT, photodynamic treatment PDT, chemical kinetics treatment CDT and the like), so as to realize combined treatment (Combination Therapy), which is considered to be one of the most promising directions for breaking through the limitation of the traditional treatment. This strategy aims at enhancing the killing effect on tumor cells through the synergistic effect of multiple mechanisms and multiple targets, and simultaneously reducing the dosage required by monotherapy, thereby reducing systemic toxic side effects. The iron-based Metal Organic Framework (MOF) has the characteristics of acid response, fenton catalytic activity, CAT activity, easy modification and the like, and is widely applied to the field of biomedicine. In recent years, the application of the multifunctional nano-platform to the combined treatment of tumors becomes a research hot spot. However, constructing truly efficient synergistic nanotherapeutic systems faces a number of technical bottlenecks. The limitation of simple physical mixing of the composite nano material is that the photothermal agent, the photosensitizer and the chemical kinetic agent are simply and physically blended, and the organic integration of functions is difficult to realize. The method is easy to cause uneven dispersion and poor stability of each component, leakage or separation occurs in the internal circulation process, and can not ensure that each treatment unit is delivered to the same tumor cell together, thereby severely restricting the realization of the synergistic treatment effect. The limitations of treatment modalities are often such that the complexity of the Tumor Microenvironment (TME) often results in failure of a monotherapy and even a significant compromise in the efficacy of a combination of therapies. For example, photothermal therapy (PTT) induces heat shock protein expression, enhances heat resistance of tumor cells, reduces treatment effect, consumes a large amount of oxygen during photodynamic therapy (PDT) to exacerbate hypoxia environment of tumor sites and further self-inhibit curative effect, and chemical kinetic therapy (CDT) has high efficiency depending on the concentration of endogenous H 2O2 and acidic environment, and high concentration of Glutathione (GSH) can scavenge generated Reactive Oxygen Species (ROS). These factors make it often difficult to achieve the synergistic effect of "1+1+1>3" with conventional combination strategies, and even "side effects" of the mutual toggle may occur. Aiming at the challenges of controllable release and targeting, how to ensure that the therapeutic agent (such as Fe ions and Ce 6) keeps stable in blood circulation, and only the specific signals (such as weak acidity, high GSH and high H 2O2) responding to TME are accurately and efficiently activated and released after reaching the tumor part is a key for reducing systematic toxicity and improving the treatment accuracy, and is a difficult problem which cannot be well solved by the prior art. Disclosure of Invention Aiming at the defects of the prior art, the invention aims to provide a novel composite nanomaterial and a preparation method thereof, so as to solve the technical problems of effective integration of multifunctional nano components, overcoming mutual inhibition among treatment modes, realizing accurate cooperative treatment under tumor microenvironment response and the like. Specifically, the invention aims to construct a stable and efficient three-function integrated nano platform through innovative material design and preparation process, and avoid the problems caused by simple mixing. By utilizing the characteristics of each component, an inherent cascade amplification synergistic mechanism is designed, so that three therapies of PTT, PDT and CDT can re